Pantec Biosolutions is granted European Patent for PLEASE

Published: 24-Sep-2009
Research & Development

Pantec Biosolutions, a Liechtenstein-based specialist in using laser microporation technology to deliver large molecular weight drugs into the human skin, has been granted a patent for the technology used in its Painless Laser Epidermal System (PLEASE) by the European Patent Office.


Pantec Biosolutions, a Liechtenstein-based specialist in using laser microporation technology to deliver large molecular weight drugs into the human skin, has been granted a patent for the technology used in its Painless Laser Epidermal System (PLEASE) by the European Patent Office.

The technology is currently in clinical trials for the delivery of IVF hormone therapy, a market with an estimated value of US$1.5-2bn.

"After receiving CE marking and marketing clearance for PLEASE last year, it is important for us to know that our key technology is now protected by patent laws," said Thomas Bragagna, chief technology officer of Pantec Biosolutions.

The company has an additional 19 applications pending in the US, Europe and Japan.

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production
  2. New NICE thresholds: good news for rare disease drugs but process remains complex Recent changes introduced by NICE will ultimately see more ultra-rare disease drugs get to market, but Dan Williams, CEO at SynaptixBio, says the process remains challenging
  3. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study
  4. Oncolytics Biotech announces positive clinical data for metastatic colorectal cancer trial The latest results could accelerate the company's path to registration after the FDA's Breakthrough Therapy designations created momentum for companies advancing pioneering oncology platforms
  5. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Drug Delivery

Rice University scientists create hydrogel platform for precision, long-lasting drug delivery

The researchers have developed a peptide hydrogel system that slows and extends drug release, improving treatment adherence and efficacy across therapies ranging from tuberculosis medication to insulin
Subscribe now